You are here


Found 778 results
[ Author(Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Nathan C.  2006.  Neutrophils and immunity: challenges and opportunities.. Nat Rev Immunol. 6(3):173-82.
Nathan C.  2012.  Fresh approaches to anti-infective therapies.. Sci Transl Med. 4(140):140sr2.
Nathan C, Cars O.  2014.  Antibiotic resistance--problems, progress, and prospects.. N Engl J Med. 371(19):1761-3.
Nathan C.  2009.  Taming tuberculosis: a challenge for science and society.. Cell Host Microbe. 5(3):220-4.
Nathan C, Nussenzweig M, Pulvirenti T.  2017.  The new face of JEM.. J Exp Med. 214(12):3467.
Nathan C.  2004.  Antibiotics at the crossroads.. Nature. 431(7011):899-902.
Nathan C.  2017.  Kunkel Lecture: Fundamental immunodeficiency and its correction.. J Exp Med. 214(8):2175-2191.
Nathan C.  2015.  Cooperative development of antimicrobials: looking back to look ahead.. Nat Rev Microbiol. 13(10):651-7.
Nathan C, Nussenzweig MC, Pulvirenti T.  2017.  JEM Advisory Editorial Board: Increasing diversity.. J Exp Med.
Nathan CF, Nussenzweig MC, Pulvirenti T.  2019.  JEM Editorial Board: Expanding on the basis of cancer.. J Exp Med. 216(8):1725.
Nathan C.  2017.  Introduction of Laurie H. Glimcher, MD.. J Clin Invest. 127(10):3575.
Nathan C, Barry CE.  2015.  TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.
Na SY, Kang BY, Chung SW, Han SJ, Ma X, Trinchieri G, Im SY, Lee JW, Kim TS.  1999.  Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB.. J Biol Chem. 274(12):7674-80.
Murray HW, Zhang Y, Zhang Y, Raman VS, Reed SG, Ma X.  2013.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.. Infect Immun. 81(7):2318-26.
Murray HW, Luster AD, Zheng H, Ma X.  2017.  Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.. Infect Immun. 85(1)
Murray HW, Xiang Z, Ma X.  2006.  Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.. Am J Trop Med Hyg. 74(6):1013-5.
Murray HW, Tsai CW, Liu J, Ma X.  2006.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.. Infect Immun. 74(7):4370-4.
Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, Ma X.  2005.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.. Infect Immun. 73(7):3903-11.
Murray HW, Mitchell-Flack M, Zheng H, Ma X.  2015.  Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.. Infect Immun. 83(2):702-12.
Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel FP.  2003.  Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.. J Infect Dis. 188(3):458-64.
Murray HW, Mitchell-Flack M, Taylor GA, Ma X.  2015.  IFN-γ-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver.. Exp Parasitol. 157:103-9.
Murray HW, Tsai CW, Liu J, Ma X.  2006.  Visceral Leishmania donovani infection in interleukin-13-/- mice.. Infect Immun. 74(4):2487-90.
Murphy M, Gomos-Klein J, Stankic M, Falck-Pedersen E.  2007.  Adeno-associated virus type 2 p5 promoter: a rep-regulated DNA switch element functioning in transcription, replication, and site-specific integration.. J Virol. 81(8):3721-30.
Murakami M, Francavilla C, Torselli I, Corada M, Maddaluno L, Sica A, Matteoli G, Iliev ID, Mantovani A, Rescigno M et al..  2010.  Inactivation of junctional adhesion molecule-A enhances antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration.. Cancer Res. 70(5):1759-65.
Mundhra S, Bryk R, Hawryluk N, Zhang T, Jiang X, Nathan C.  2018.  Evidence for dispensability of protein kinase R in host control of tuberculosis.. Eur J Immunol. 48(4):612-620.